Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada |
| |
Authors: | Reid Robert L Fortier Michel P Smith Lynne Mirkin Sebastian Grubb Gary S Constantine Ginger D |
| |
Affiliation: | aDepartment of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada K7L 4V7;bClinique de Recherche en Santé des femmes, Québec, Québec, Canada G1S 2L6;cPfizer, Inc., Collegeville, PA 19101, USA;dWyeth Research (formerly), Collegeville, PA 19101, USA |
| |
Abstract: | BackgroundThe study was conducted to evaluate bleeding profile and safety of continuous oral contraceptive (OC) containing levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg.Study DesignHealthy women who participated at seven Canadian sites in 1-year open-label study of LNG 90 mcg/EE 20 mcg daily were eligible for this second-year extension study. Primary end points included bleeding profile and adverse events.ResultsSeventy-nine women enrolled without interrupting pill taking; 62 (78.5%) completed. Adverse events were comparable to cyclic OC regimens, except unscheduled vaginal bleeding. Amenorrhea and absence of bleeding increased to about 80% and 90%, respectively, by Pill Pack 18. Mean (median) number of bleeding days for the last two 90-day intervals was 1.1 (0) and 0.7 (0) days, respectively.ConclusionsContinuous LNG 90 mcg/EE 20 mcg had a safety profile similar to low-dose cyclic OCs. Short-term safety profile remained excellent, with increasing rates of amenorrhea and decreasing incidence of unscheduled bleeding and/or spotting. |
| |
Keywords: | Continuous oral contraceptive Levonorgestrel Ethinyl estradiol Bleeding Safety |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|